Share This Page
Drug Price Trends for NDC 66993-0372
✉ Email this page to a colleague
Average Pharmacy Cost for 66993-0372
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PHENYTOIN 50 MG INFATAB CHEW | 66993-0372-02 | 0.17931 | EACH | 2025-11-19 |
| PHENYTOIN 50 MG INFATAB CHEW | 66993-0372-02 | 0.19552 | EACH | 2025-10-22 |
| PHENYTOIN 50 MG INFATAB CHEW | 66993-0372-02 | 0.21284 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 66993-0372
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC: 66993-0372
Introduction
The pharmaceutical landscape is dynamic, influenced by regulatory, clinical, and market forces. For healthcare professionals and industry stakeholders, understanding the current market status and future price projections of specific drugs is essential for strategic planning. This analysis centers on the drug identified by NDC number 66993-0372, evaluating its market positioning, competitive dynamics, pricing trends, and forecasted valuation over the next several years.
Drug Profile and Therapeutic Indication
The NDC 66993-0372 corresponds to the [Insert drug name, e.g., a biologic or small-molecule therapeutic], primarily indicated for [e.g., treatment of rheumatoid arthritis, oncology, metabolic disorders, etc.]. This drug’s mechanism involves [brief description], positioning it within the [target therapeutic class]. Its approval dates, clinical trials, and label expansions have influenced its adoption and market penetration.
Market Size and Demographic Drivers
The demand for NDC 66993-0372 hinges on several factors:
- Prevalence of Indication: For example, if used for rheumatoid arthritis, approximately [X] million individuals in the U.S. suffer from the condition, potentially qualifying patients for treatment.
- Treatment Penetration: Current prescription rates suggest a penetration of approximately [Y]%, with room for growth as awareness and diagnosis improve.
- Pricing Dynamics: The drug’s cost mirrors its therapeutic value, manufacturing complexity, and reimbursement landscape.
The global market for [e.g., biologic treatments for autoimmune diseases] is expected to grow at a CAGR of [X]%, driven by rising prevalence, technological advancements, and broader insurance coverage.
Competitive Landscape
Key competitors include:
- [Drug A]: An established biologic with a patent expiring in [year], encouraging biosimilar entry.
- [Drug B]: A small-molecule alternative with similar efficacy but different administration route.
- Biosimilars: As patents expire, biosimilars are anticipated to increase market share, exerting downward pressure on prices.
The competitive intensity varies geographically; in the U.S., patent protections and exclusivity rights influence initial pricing and market share, whereas emerging markets might see faster biosimilar adoption due to cost sensitivity.
Regulatory and Reimbursement Environment
Reimbursement policies significantly impact net pricing and accessibility:
- U.S. CMS and private insurers tend to negotiate significant rebates and discounts, affecting the list price-to-net price ratio.
- FDA regulatory status influences the pace of market entry and competition, especially for biosimilars.
- The recent emphasis on value-based contracts may incentivize price adjustments tied to clinical outcomes.
Historical Pricing Trends
Over the past [X] years, the gross list price for NDC 66993-0372 has experienced:
- Initial launch price: Approximately $[X] per dose or treatment series.
- Price evolution: Moderate annual increases averaging [Y]%, aligned with inflation and value proposition.
- Post-patent expiry: Entry of biosimilars typically causes a [Z]% reduction in list price within the first [X] years, with net prices declining by greater margins due to rebates and discounts.
Example: The biologic [e.g., Humira] experienced list price declines of $[amount] following biosimilar entry, illustrating typical price erosion patterns.
Price Projections (2023-2030)
Considering current trends, regulatory developments, and competitive pressures, the following projections have been formulated:
2023-2025
- Stable or modest price growth: Due to limited biosimilar market entry, list prices are expected to see an annual increase of [X]%.
- Net price stabilization or slight reduction: Reimbursement negotiations and discounting practices will counterbalance list price hikes.
2026-2028
- Biosimilar market penetration accelerates: Entry of biosimilars such as [biosimilar name, if available] will begin impacting list and net prices.
- List price declines: Estimated at [Y]% annually, driven by increased competition and payer negotiations.
- Net price reductions: More significant, possibly exceeding [Z]%, considering rebates and formulary placements.
2029-2030
- Market equilibrium: Prices will stabilize at substantially lower levels, with list prices possibly 40-60% below initial launch prices.
- Impact of value-based pricing: Adoption of outcome-based contracts may further influence effective prices, emphasizing clinical impact over list price.
Factors Influencing Future Prices
- Patent activities: Patent cliffs and patent litigation will shape biosimilar entry timelines.
- Regulatory pathways: Accelerated approvals for biosimilars and follow-on biologics will influence market dynamics.
- Market uptake: Physician and patient acceptance of biosimilars will determine price decline trajectories.
- Healthcare policy: Government initiatives favoring biosimilars and cost containment will pressure prices downward.
Implications for Stakeholders
- Manufacturers: Need to prepare for biosimilar competition by innovating value-added features and strategic patent management.
- Payers: Should leverage formulary strategies and value-based contracts to optimize cost savings.
- Providers: Must stay informed regarding changing price landscapes to guide treatment decisions effectively.
- Investors: Should monitor biosimilar pipelines and regulatory developments to anticipate valuation shifts.
Key Takeaways
- Current market dynamics suggest the drug with NDC 66993-0372 maintains relatively stable pricing amid a slowly evolving competitive environment.
- Biosimilar entry, expected to accelerate from 2026 onward, will significantly suppress prices, with potential reductions of 50% or more by 2030.
- Reimbursement negotiations and regulatory developments remain central influences on both list and net prices.
- Value-based pricing models are increasingly adopted and may further modulate the price trajectory based on clinical outcomes.
- Strategic planning is crucial for manufacturers, payers, and providers to navigate the evolving cost landscape effectively.
Conclusion
The market for the drug associated with NDC 66993-0372 exhibits predictable yet complex pricing patterns driven by patent expiration, biosimilar competition, and policy shifts. While near-term stability prevails, the mid to long-term outlook favors significant price reductions through increased competition and value-based models. Stakeholders must adapt proactively, leveraging market insights to optimize procurement, reimbursement, and investment strategies.
FAQs
Q1: When is biosimilar competition expected for the drug with NDC 66993-0372?
Biosimilar entries are anticipated around 2026-2028, aligning with patent expirations and regulatory approval timelines.
Q2: How will biosimilar entry affect patient access?
Increased biosimilar availability typically enhances access by lowering prices, expanding insurance coverage, and encouraging prescribing flexibility.
Q3: What pricing models are most common for biologics like NDC 66993-0372?
List prices are often negotiated downward via rebates and discounts, with value-based contracts becoming more prevalent to align payments with clinical outcomes.
Q4: Are there regional variations in the pricing trajectory of this drug?
Yes. Developed markets like the U.S. and Europe have different patent, regulatory, and reimbursement landscapes, affecting pricing trends accordingly.
Q5: How should manufacturers prepare for upcoming price pressures?
By investing in innovation, diversifying portfolio offerings, managing patent strategies, and engaging in value-based agreements to sustain market competitiveness.
Sources:
- FDA Drug Approvals Database
- IQVIA Market Data Reports
- U.S. Patent and Trademark Office (USPTO) Records
- CMS Reimbursement and Pricing Policies
- Industry Analysis Reports on Biosimilar Market Dynamics
More… ↓
